{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:57:37Z","timestamp":1792022257745,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Ethnopharmacology"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.jep.2004.02.012","type":"journal-article","created":{"date-parts":[[2004,4,13]],"date-time":"2004-04-13T06:22:09Z","timestamp":1081837329000},"page":"147-162","source":"Crossref","is-referenced-by-count":476,"title":["Galanthamine from snowdrop\u2014the development of a modern drug against Alzheimer\u2019s disease from local Caucasian knowledge"],"prefix":"10.1016","volume":"92","author":[{"given":"Michael","family":"Heinrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooi","family":"Lee Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jep.2004.02.012_BIB1","first-page":"1117","article-title":"Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function","volume":"280","author":"Albuquerque","year":"1997","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jep.2004.02.012_BIB2","doi-asserted-by":"crossref","unstructured":"Alzheimer, A. \u00dcber eine eigenartige Erkrankung der Hirnrinde Allgemeine Zeitschrift fuer Psychiatrie und psychisch-gerichtliche Medizin 64, 146\u2013148 (English translation: Alzheimer, A., Stelzmann, R.A., Schnitzlein, H.N., Murtagh, F.R. (Trans.), 1995. An English translation of Alzheimer\u2019s 1907 paper, about a peculiar disease of the cerebral cortex. Clinical Anatomy 8, 429\u2013431).","DOI":"10.1002\/ca.980080612"},{"key":"10.1016\/j.jep.2004.02.012_BIB3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00008571-199912000-00001","article-title":"The O-demethylation of the anti-dementia drug galanthamine is catalysed by cytochrome P450 2D6","volume":"9","author":"Bachus","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jep.2004.02.012_BIB4","doi-asserted-by":"crossref","unstructured":"Bandman, A.L., Anriiyanov, A.I., 1982. Effect on benactyzine and galanthamine on behavioral effects of apomorphine in rats. Bulletin of Experimental Biology and Medicine (Byulleten Eksperimentalnoi Biologii i Meditsiny, Russia) 92, 1522\u20131525.","DOI":"10.1007\/BF00829890"},{"key":"10.1016\/j.jep.2004.02.012_BIB5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/clpt.1991.159","article-title":"Pharmacokinetics of galanthamine in human and corresponding cholinesterase inhibition","volume":"50","author":"Bickel","year":"1991","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.jep.2004.02.012_BIB6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0028-3908(91)90005-V","article-title":"Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice","volume":"30","author":"Bickel","year":"1991","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jep.2004.02.012_BIB7","unstructured":"BNF (British National Formulary), 2002. Galanthamine. British National Formulary. The British Medical Association, Royal Pharmaceutical Society of Great Britain, 44th ed. The Pharmaceutical Press, London, p. 253."},{"key":"10.1016\/j.jep.2004.02.012_BIB8","first-page":"728","article-title":"Pharmacological evaluation of novel Alzheimer\u2019s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine","volume":"227","author":"Bores","year":"1996","journal-title":"Journal of Pharmacology and Experimental Therapeutic"},{"key":"10.1016\/j.jep.2004.02.012_BIB9","unstructured":"Bouchard, R.W., Rossor, M., 1996. Typical clinical features. In: Gauthier, S. (Ed.), Clinical Diagnosis and Management of Alzheimer\u2019s Disease. Martin Dunitz, London, pp. 35\u201351."},{"key":"10.1016\/j.jep.2004.02.012_BIB10","first-page":"23","article-title":"Phytochemical study on Galanthus nivalis var. gracilis","volume":"2","author":"Bubeva-Ivanova","year":"1957","journal-title":"Pharmacia"},{"key":"10.1016\/j.jep.2004.02.012_BIB11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF02253584","article-title":"Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats","volume":"106","author":"Chopin","year":"1992","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jep.2004.02.012_BIB12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm0498-452","article-title":"A variant of Alzheimer\u2019s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1","volume":"4","author":"Crook","year":"1998","journal-title":"Nature Medicine"},{"key":"10.1016\/j.jep.2004.02.012_BIB13","doi-asserted-by":"crossref","unstructured":"Dal-Bianco, P., Maly, J., Wober, C., Lind, C., Koch, G., Hufgard, J., Marschall, I., Mraz, M., Deecke, L., 1991. Galanthamine treatment in Alzheimer\u2019s disease. Journal of Neural Transmission (Suppl. l33) 59\u201363.","DOI":"10.1007\/978-3-7091-9135-4_10"},{"key":"10.1016\/j.jep.2004.02.012_BIB14","unstructured":"Effron, D., Farber, S.M., Holmstedt, B., Kline, N.L., Wilson, R.H.L., 1970. Ethnopharmacologic Search for Psychoactive Drugs. Government Printing Office, Washington, DC. Public Health Service Publications No. 1645 (orig. 1967) (reprint)."},{"key":"10.1016\/j.jep.2004.02.012_BIB15","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomised trial","volume":"359","author":"Erkinjunti","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jep.2004.02.012_BIB16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2307\/3350099","article-title":"Estimated prevalence of Alzheimer\u2018s disease in the United States","volume":"68","author":"Evans","year":"1990","journal-title":"Milbank Quarterly"},{"key":"10.1016\/j.jep.2004.02.012_BIB17","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1001\/jama.262.18.2551","article-title":"Prevalence of Alzheimer\u2019s disease in a community population of older persons. Higher than previously reported","volume":"262","author":"Evans","year":"1989","journal-title":"Journal of American Medical Association"},{"key":"10.1016\/j.jep.2004.02.012_BIB18","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1001\/jama.268.18.2523","article-title":"A controlled trial of tacrine in Alzheimer\u2019s disease: the Tacrine Study Group","volume":"268","author":"Farlow","year":"1992","journal-title":"Journal of American Medical Association"},{"key":"10.1016\/j.jep.2004.02.012_BIB19","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1016\/S0149-2918(01)80164-8","article-title":"Pharmacokinetics profiles of current therapies for AD: implications for switching to galanthamine","volume":"23","author":"Farlow","year":"2001","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.jep.2004.02.012_BIB20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0163-1047(93)90886-M","article-title":"d-Cycloserine attenuates scopolamine-induced learning and memory deficits in rats","volume":"59","author":"Fishkin","year":"1993","journal-title":"Behavioral and Neural Biology"},{"key":"10.1016\/j.jep.2004.02.012_BIB21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatry Research"},{"key":"10.1016\/j.jep.2004.02.012_BIB22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2165\/00002512-199609010-00006","article-title":"Galanthamine","volume":"9","author":"Fulton","year":"1996","journal-title":"Drugs and Aging"},{"key":"10.1016\/j.jep.2004.02.012_BIB23","doi-asserted-by":"crossref","unstructured":"Giacobini, E., 1991. The second generation of cholinesterase inhibitiors: pharmacological aspects. In: Becker, R., Giacobini, E. (Eds.), Cholinergic Basis for Alzheimer Therapy. Birkh\u00e4user, Boston, pp. 247\u201362.","DOI":"10.1007\/978-1-4899-6738-1_29"},{"key":"10.1016\/j.jep.2004.02.012_BIB24","unstructured":"Giacobini, E., 2000. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini, E.E., et al. (Eds.), Cholinesterases and Cholinesterase Inhibitors. Martin Dunitz, London, pp. 181\u2013226."},{"key":"10.1016\/j.jep.2004.02.012_BIB25","first-page":"712","article-title":"Erfahrung mit Nivalin in der neuologischen Therapie. Bericht \u00fcber 100 F\u00e4lle","volume":"23","author":"G\u00f6pel","year":"1971","journal-title":"Psychiatrische Neurologie und medizinische Psychologie (Leipzig)"},{"key":"10.1016\/j.jep.2004.02.012_BIB26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0163-7258(95)02002-0","article-title":"The pharmacology of galanthamine and its analogues","volume":"68","author":"Harvey","year":"1995","journal-title":"Pharmacology Therapeutics"},{"key":"10.1016\/j.jep.2004.02.012_BIB27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1211\/0022357011775712","article-title":"Ethnopharmacology in drug discovery: an analysis of its role and potential contributions","volume":"53","author":"Heinrich","year":"2001","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.jep.2004.02.012_BIB28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/oxfordjournals.bmb.a072106","article-title":"Cholinergic approaches to the treatment of Alzheimer\u2019s disease","volume":"42","author":"Hollander","year":"1986","journal-title":"British Medical Bulletin"},{"key":"10.1016\/j.jep.2004.02.012_BIB29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1358\/dot.1997.33.4.425052","article-title":"Pharmacokinetics and metabolism of galanthamine","volume":"33","author":"Kewitz","year":"1997","journal-title":"Drugs of Today"},{"key":"10.1016\/j.jep.2004.02.012_BIB30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jama.271.13.985","article-title":"A 30-week randomized controlled trial of high dose tacrine in patients with Alzheimer\u2019s disease: the Tacrine Study Group","volume":"271","author":"Knapp","year":"1994","journal-title":"Journal of American Medical Asociation"},{"key":"10.1016\/j.jep.2004.02.012_BIB31","first-page":"S22","article-title":"Efficacy and safety of high-dose tacrine: a 30-week evaluation","volume":"8","author":"Knapp","year":"1994","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1016\/j.jep.2004.02.012_BIB32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/00001756-199704140-00043","article-title":"Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer\u2019s disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype","volume":"8","author":"Kwok","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.jep.2004.02.012_BIB33","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/A:1022419712453","article-title":"The cognitive psychopharmacology of Alzheimer\u2019s Disease: focus on cholinergic systems","volume":"23","author":"Lawrence","year":"1998","journal-title":"Neurochemistry Research"},{"key":"10.1016\/j.jep.2004.02.012_BIB34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s002130050667","article-title":"Nicotinic acetylcholine involvement in cognitive function in animals","volume":"138","author":"Levin","year":"1998","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jep.2004.02.012_BIB35","unstructured":"Madaus, G., 1938 [2002]. Lehrbuch der biologischen Heilmittel. Nachdr. d. Ausg. Leipzig 1938. Mediamed, Ravensburg."},{"key":"10.1016\/j.jep.2004.02.012_BIB36","unstructured":"Marzell, H., 2002. Geschichte und Volkskunde der deutschen Heilpflanzen. Reich Verlag, St. Goar (orig. 1938)."},{"key":"10.1016\/j.jep.2004.02.012_BIB37","first-page":"21","article-title":"Effects of galanthamine on acetylcholine sensitivity of skeletal musculature","volume":"18","author":"Mashkovsky","year":"1955","journal-title":"Farmakologiia i Toksikologia (Moskow)"},{"key":"10.1016\/j.jep.2004.02.012_BIB38","first-page":"27","article-title":"On the pharmacology of the new alkaloid galantamine","volume":"14","author":"Mashkovsky","year":"1951","journal-title":"Farmakologia Toxicologia (Moskow)"},{"key":"10.1016\/j.jep.2004.02.012_BIB39","unstructured":"Mayrhofer, O. 1967. Nivalin\u2014experience with application of galanthamine as an antagonist to the relaxants of curare type. Bulletin of the Swiss Academy of Medical Sciences, vol. 23, fasc. 1\/2, pp. 48\u201352."},{"key":"10.1016\/j.jep.2004.02.012_BIB40","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer\u2019s disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.jep.2004.02.012_BIB41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000138571","article-title":"Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans","volume":"39","author":"Mihailova","year":"1989","journal-title":"Pharmacology"},{"key":"10.1016\/j.jep.2004.02.012_BIB42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/0024-3205(81)90674-3","article-title":"Partial reversal of anticholinergic amnesia by choline chloride","volume":"29","author":"Mohs","year":"1981","journal-title":"Life Sciences"},{"key":"10.1016\/j.jep.2004.02.012_BIB43","first-page":"87","article-title":"Nivalin treatment of patients with diseases of nervous system","volume":"15","author":"Nastev","year":"1960","journal-title":"Cultura Medica (Roma)"},{"key":"10.1016\/j.jep.2004.02.012_BIB44","unstructured":"Pabst, G. 1889. K\u00f6hler\u2019s Medizinal-Pflanzen in naturgetreuen Abbildungen mit kurz erl\u00e4uterndem Texte: Atlas zur Pharmacopoea Germanica, Austriaca, Belgica, Danica, Helvetica, Hungarica, Rossica, Suecica, Neerlandica, British pharmacopoeia, zum Codex medicamentarius sowie zur Pharmacopoeia of the United States of America. Gera-Untermhaus, K\u00f6hler."},{"key":"10.1016\/j.jep.2004.02.012_BIB45","first-page":"S19","article-title":"Development of Reminyl\u00ae (galanthamine), a novel acetylcholinesterase inhibitor, for the treatment of Alzheimer\u2019s Disease","volume":"53","author":"Parys","year":"1998","journal-title":"Alzheimer\u2019s Reports"},{"key":"10.1016\/j.jep.2004.02.012_BIB46","first-page":"29","article-title":"Effect of galanthamine on the skeletal muscles. Proceedings of the Department of Biological and Medical Sciences at the Bulgarian Academy of Sciences","volume":"1","author":"Paskov","year":"1957","journal-title":"Series Experimental Biology and Medicine (Sofia)"},{"key":"10.1016\/j.jep.2004.02.012_BIB47","unstructured":"Paskov, D.S., 1959. Nivalin: Pharmacology and Clinical Application. Medicina i Fizkultura, Sofia."},{"key":"10.1016\/j.jep.2004.02.012_BIB48","doi-asserted-by":"crossref","unstructured":"Paskov, D.S., 1986. Galanthamine. In: Kharkevich, D.A. (Ed.), Handbook of Experimental Pharmacology. Springer, Berlin-Heidelberg, New York, Tokyo (Chapter 31), pp. 653\u2013672.","DOI":"10.1007\/978-3-642-70682-0_31"},{"key":"10.1016\/j.jep.2004.02.012_BIB49","first-page":"1474","article-title":"Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons","volume":"265","author":"Pereira","year":"1993","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jep.2004.02.012_BIB50","unstructured":"Pharmaproject\u00ae, 2003. Drug Profile: Galanthamine. PJB Publications Ltd. Accessed 25th February 2003."},{"key":"10.1016\/j.jep.2004.02.012_BIB51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-198303000-00001","article-title":"Homer\u2019s moly identified as Galanthus nivalis L.: physiologic antidote to stramonium poisoning","volume":"6","author":"Plaitakis","year":"1983","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.jep.2004.02.012_BIB52","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1097\/00002826-199013003-00008","article-title":"Neurochemical deficits in pathological brain aging: specificity and possible relevance for treatment strategies","volume":"13","author":"Quirion","year":"1990","journal-title":"Journal of Clinical Neuropharmacology"},{"key":"10.1016\/j.jep.2004.02.012_BIB53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00023210-199707020-00001","article-title":"Galanthamine in AD\u2014a new alternative to tacrine?","volume":"7","author":"Rainer","year":"1997","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jep.2004.02.012_BIB54","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galanthamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jep.2004.02.012_BIB55","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galanthamine dose in Alzheimer\u2019s disease: a randomized, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"Journal of Neurosurgery Psychiatry"},{"key":"10.1016\/j.jep.2004.02.012_BIB56","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jep.2004.02.012_BIB57","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1212\/WNL.35.8.1089","article-title":"Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of the Alzheimer\u2019s type: possible role in cell loss","volume":"35","author":"Saper","year":"1985","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.jep.2004.02.012_BIB58","first-page":"1","article-title":"Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands","volume":"49","author":"Schrattenholz","year":"1996","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.jep.2004.02.012_BIB59","first-page":"883","article-title":"Alkaloids from snowdrops","volume":"264","author":"Shellard","year":"2000","journal-title":"The Pharmaceutical Journal"},{"key":"10.1016\/j.jep.2004.02.012_BIB60","unstructured":"Sopharma USA Corporation. Galanthamine: introduction. URL: http:\/\/bpg.bg\/nivalin\/introduction.htm (accessed 18th February 2003)."},{"key":"10.1016\/j.jep.2004.02.012_BIB61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0922-4106(95)00080-1","article-title":"Physostigmine, galanthamine and codeine act as \u2018noncompetitive nicotinic receptors agonists\u2019 on clonal rat pheochromocytoma cells","volume":"290","author":"Storch","year":"1995","journal-title":"European Journal of Pharmacology\u2014Pharmacology Section"},{"key":"10.1016\/j.jep.2004.02.012_BIB62","first-page":"217","article-title":"Galanthaminum hydrobromicum \u201cNivalin\u201d, ein neues Antidot der nichtdepolarisierenden Muskelrelaxantien. Pharmakologie und klinische Anwendung","volume":"13","author":"Stoyanov","year":"1964","journal-title":"Der Anaesthesist"},{"key":"10.1016\/j.jep.2004.02.012_BIB63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0091-3057(88)90325-5","article-title":"A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice","volume":"31","author":"Sweeney","year":"1988","journal-title":"Pharmacology, Biochemistry and Behavior"},{"key":"10.1016\/j.jep.2004.02.012_BIB64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0091-3057(89)90364-X","article-title":"Galanthamine, an acetylcholinesterase inhibitor: a time course of the course of the effects on performance and neurochemical parameters in mice","volume":"34","author":"Sweeney","year":"1989","journal-title":"Pharmacology, Biochemistry and Behavior"},{"key":"10.1016\/j.jep.2004.02.012_BIB65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF02245921","article-title":"Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice","volume":"102","author":"Sweeney","year":"1990","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jep.2004.02.012_BIB66","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month randomized, placebo-controlled trial of galanthamine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jep.2004.02.012_BIB67","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/0024-3205(90)90429-U","article-title":"Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo","volume":"46","author":"Thomsen","year":"1990","journal-title":"Life Sciences"},{"key":"10.1016\/j.jep.2004.02.012_BIB68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0006-2952(91)90022-W","article-title":"In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers","volume":"41","author":"Thomsen","year":"1991","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.jep.2004.02.012_BIB69","first-page":"487","article-title":"Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine","volume":"29","author":"Thomsen","year":"1991","journal-title":"European Journal of Clinical Biochemistry"},{"key":"10.1016\/j.jep.2004.02.012_BIB70","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(77)92114-6","article-title":"Neocortical cholinergic neurons in elderly people","volume":"1","author":"White","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.jep.2004.02.012_BIB71","first-page":"19","article-title":"The cholinergic deficit in Alzheimer\u2019s disease","volume":"59","author":"Whitehouse","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jep.2004.02.012_BIB72","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.410100203","article-title":"Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis","volume":"10","author":"Whitehouse","year":"1981","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.jep.2004.02.012_BIB73","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galanthamine in patients with mild to moderate Alzheimer\u2019s disease: multicentre, randomized, controlled trial: Galanthamine International-1 Study group","volume":"321","author":"Wilcock","year":"2000","journal-title":"British Medical Journal"},{"key":"10.1016\/j.jep.2004.02.012_BIB74","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galanthamine: a randomised, double-blind, dose comparison in patients with Alzheimer\u2019s disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.jep.2004.02.012_BIB75","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1073\/pnas.031584398","article-title":"Galanthamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning","volume":"98","author":"Woodruff-Pak","year":"2001","journal-title":"Proceedings of the National Academy Sciences of the United States of America"},{"key":"10.1016\/j.jep.2004.02.012_BIB76","first-page":"2209","article-title":"Age-related loss of calbindin from human basal forebrain cholinergic neurons","volume":"8","author":"Wu","year":"1997","journal-title":"Neurology Report"},{"key":"10.1016\/j.jep.2004.02.012_BIB77","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/0091270002424009","article-title":"Pharmacokinetics and safety in subjects with hepatic impairment and healthy volunteers","volume":"42","author":"Zhao","year":"2002","journal-title":"Journal of Clinical Pharmacology"}],"container-title":["Journal of Ethnopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037887410400073X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037887410400073X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T19:54:30Z","timestamp":1585684470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037887410400073X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":77,"aliases":["10.1016\/s0378-8741(04)00073-x"],"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S037887410400073X"],"URL":"https:\/\/doi.org\/10.1016\/j.jep.2004.02.012","relation":{},"ISSN":["0378-8741"],"issn-type":[{"value":"0378-8741","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}